Mianserin is a tetracyclic antidepressant developed in the 1960s and introduced into clinical use in the 1970s for the treatment of depressive disorders. Its history is characterized by its alternative mechanism compared to traditional tricyclic antidepressants, offering antidepressant effects with a different side effect profile, particularly with less anticholinergic activity. Mianserin acts primarily by modulating central monoaminergic neurotransmission, especially involving noradrenergic and serotonergic pathways. Over time, its use has been influenced by the development of newer antidepressants, but it remains an option in certain clinical settings where sedation or alternative antidepressant mechanisms are desired.
BRAND NAMES
Tolvon – one of the most widely recognized international brands
Lerivon – commonly used in several European and other markets
Bolvidon – another branded formulation available in select regions.
MECHANISM OF ACTION
Mianserin acts primarily by enhancing central monoaminergic neurotransmission. It functions as an antagonist at presynaptic alpha-2 adrenergic receptors, which increases the release of norepinephrine and serotonin in the central nervous system. Additionally, it blocks certain serotonin receptors (especially 5-HT2 and 5-HT3), contributing to its antidepressant and anxiolytic effects while reducing some serotonergic side effects. Its antihistaminic (H1 receptor blockade) activity is responsible for its sedative properties.
PHARMACOKINETICS
Absorption
Mianserin is well absorbed after oral administration, with moderate bioavailability due to first-pass hepatic metabolism. Peak plasma concentrations are typically reached within a few hours after dosing.
Distribution
It is widely distributed in body tissues and is highly lipophilic, allowing penetration into the central nervous system. Plasma protein binding is moderate to high.
Metabolism
Mianserin is extensively metabolized in the liver, primarily via oxidative pathways, producing inactive metabolites. Hepatic metabolism plays a major role in drug clearance.
Elimination
Excretion occurs mainly through the urine as metabolites, with a smaller portion eliminated in feces. The elimination half-life allows for once- or twice-daily dosing depending on clinical response.
PHARMACODYNAMICS
Mianserin increases central norepinephrine and serotonin levels by blocking presynaptic alpha-2 adrenergic inhibitory feedback. It also antagonizes specific serotonin receptors (5-HT2 and 5-HT3), which enhances antidepressant efficacy and reduces anxiety and gastrointestinal side effects. Its strong antihistamine activity contributes to sedation, which can be beneficial in patients with insomnia associated with depression.
ADMINISTRATION
Mianserin is administered orally in tablet form. It is usually given once daily at night due to its sedative effects, although dosing may be divided depending on clinical needs. Treatment is typically started at a low dose and gradually adjusted based on patient response.
DOSAGE AND STRENGTH
Common adult dosing ranges from 30–90 mg per day, often starting at a lower dose (e.g., 10–30 mg) and titrated upward. Elderly patients or those sensitive to sedation may require lower doses.
DRUG INTERACTIONS
Mianserin may interact with CNS depressants (such as alcohol, benzodiazepines, or sedatives), leading to enhanced sedation. It may also interact with other serotonergic or adrenergic drugs, requiring careful monitoring.
FOOD INTERACTIONS
Food does not significantly affect absorption. However, alcohol should be avoided as it can enhance sedative effects and impair central nervous system function.
CONTRAINDICATIONS
Mianserin is contraindicated in patients with known hypersensitivity to the drug and should be used cautiously in individuals with severe hepatic impairment or blood dyscrasias, as rare hematological effects have been reported.
SIDE EFFECTS
Common side effects include sedation, drowsiness, weight gain, dry mouth, dizziness, and increased appetite. Less commonly, it may cause orthostatic hypotension or mild gastrointestinal disturbances.
OVER DOSAGE
Overdose of Mianserin is usually characterized by central nervous system depression and cardiovascular effects. Clinical features may include severe drowsiness, sedation, confusion, dizziness, hypotension, tachycardia, and impaired coordination. In more serious cases, especially with very high doses or co-ingestion of alcohol or other CNS depressants, patients may develop coma, respiratory depression, or seizures.
TOXICITY
Toxicity of Mianserin is generally related to excessive CNS depression, presenting as severe drowsiness, confusion, hypotension, and in rare cases cardiac effects or seizures. Overdose is managed with supportive care, including airway protection, cardiovascular monitoring, and symptomatic treatment. Severe toxicity is uncommon but may be enhanced when combined with other sedatives or alcohol.
